Adhering to the enterprise tenet of "creating value for society and customers to realize the value of employees and enterprise", LBP focuses on the business development of in vitro diagnosis, especially pathological diagnosis products related to tumor diseases, promotes R&D innovation and the industrialization of technological achievements vigorously, strengthens the construction of a multi-level marketing network, builds an innovative business model of online and offline integrated with vitro diagnosis ecosystem, accelerates the cultivation of the in vitro diagnosis market and continuously enhances its brand influence of LBP. It is committed to becoming a leading enterprise integrating R&D, production, sales, service and education & training of pathological diagnosis technology in China.
Guangzhou LBP Medicine Science & Technology Co., Ltd. is a high-tech enterprise specializing in the research & development, production and service of pathological diagnostic products in China, and also the only leading enterprise in the pathological diagnostic industry in China with the research and production capacity of multi-technology platform-based pathological diagnostic equipment + pathological diagnostic reagents. Its main businesses are the research & development, production and service of self-owned brand in vitro diagnostic reagents and equipment. LBP independently developed core technology platforms of liquid-based cytology, immunohistochemistry and molecular gene diagnosis have formed a full range of pathological diagnostic reagents and fully automated pathological diagnostic equipment, including liquid-based cytology, immunohistochemistry (IHC), real-time fluorescence quantitative PCR, reverse dot blot, fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS), covering morphological diagnosis, protein analysis and molecular pathological diagnosis.
Guangzhou Jehomelab Network Technology Co., Ltd. is one of the first companies in China to provide a brand new "Internet + medical" mode. Jehomelab will use the advantageous resources of LBP in the field of pathological diagnosis, and cooperate with Guangzhou LBP Laboratory Co., Ltd. and local medical institutions to provide more convenient, fast and professional medical testing services and health management services for the public.
Guangzhou Jianyi Medical Technology Co., Ltd. is a wholly-owned subsidiary of Guangzhou LBP Medical Technology Co., Ltd. With the help of the resources and strength of LBP in the medical industry, Jianyi cooperated with domestic first-class hospitals to create the first health network platform providing medical testing, diagnosis and treatment services for first-class hospitals in China. Let us enjoy one-stop high-quality health services at home and consultation, testing, diagnosis and treatment, and medication.
LBP was founded in 2005 and focuses on tumor screening and accurate diagnosis.
Now we have independently developed a series of reagents and supporting equipment, mainly in the department of pathology. The product lines of liquid-based cytology (LBP), polymerase chain reaction (PCR), immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) have been established, covering the clinical needs of tumor screening and diagnosis at different diagnostic levels from cell morphology to protein expression and gene detection. Some of our products have been certified by CE , British Standards Institute (BSI) and Japanese Ministry of Health, Labor and Welfare. It is one of the enterprises with the most abundant technology platform and the largest product variety in the cancer screening and diagnosis industry in China.
In order to improve the "automation, standardization, digitalization and intellectualization" level of pathology department, LBP has launched a series of digital pathology products, among which pathological medical image analysis and processing system and automatic digital slice scanning system have been certified and marketed. At the same time, LBP actively responds to the national policy of quality medical resources sinking and promoting hierarchical diagnosis and treatment, constantly expands pathology service business, and helps improve the diagnostic ability of pathology departments in grassroots hospitals. In order to promote the accurate matching of drugs for cancer patients, the company is also actively expanding the business of accompanying diagnosis for pharmaceutical companies.
LBP always adheres to the purpose of "creating value for society and customers, in order to realize the value of employees and enterprises", commits itself to becoming a leading enterprise in the field of pathological diagnosis, and realizes the corporate vision of "Benefiting society with precision medicine diagnosis".
Reasonable, Caring for others, Unremitting, Innovative ,Self-transcendent
Create the value for society and customers to fulfill the value of employees and company.
